SI-BONE, Inc. (SIBN) Company Overview

What does SI-BONE do?

SI-BONE, Inc. is a Nasdaq-listed medical-device company focused on the sacroiliac joint, spinopelvic fixation, and pelvic trauma. It pioneered minimally invasive SI joint fusion, then extended anatomy-specific titanium implant design into adjacent sacropelvic procedures. Its common stock trades on the Nasdaq Global Market under SIBN, as confirmed in its latest Form 10-Q.

Which products define the platform?

The portfolio is a progression of titanium implants, porous surfaces, instruments, physician training, and procedure-specific clearances. The 2025 Form 10-K describes patented implants, implantation instruments, and implantable bone products.

How does SI-BONE make money?

SI-BONE earns revenue when implants are used in surgical or interventional procedures. Most U.S. revenue is recognized after implantation and customer authorization; a smaller share is recognized when products ship to agents or facilities ordering in advance. Revenue therefore depends on procedure volume, implants per case, product mix, pricing, site of care, geography, and sales channel.

Which revenue drivers matter most?

The principal drivers are active physicians, procedures per physician, territory productivity, and portfolio breadth. Adoption can become repeatable because trained physicians perform multiple cases and facilities retain instrument access. Growth still depends on reimbursement: hospitals and physicians need adequate payment for the procedure, not merely interest in the implant.

How concentrated is the business geographically?

The United States remains the economic engine. In FY2025, U.S. sales were $191.1 million, or 95% of worldwide revenue, versus $9.8 million, or 5%, internationally. This scale also concentrates exposure to U.S. coverage, coding, hospital budgets, and physician adoption. International expansion adds diversification but also regulatory, distribution, currency, and reimbursement complexity.

What did SI-BONE’s latest quarter show?

The quarter ended March 31, 2026 showed continued double-digit growth, stable gross economics, and improving losses. SI-BONE’s first-quarter 2026 earnings release reported worldwide revenue of $52.6 million, up 11.2% year over year. U.S. revenue was $49.3 million, up 10.0%, while international revenue reached $3.3 million, up 33.9%.

How did profitability and operating leverage change?

Gross profit was $41.9 million at a 79.8% margin. Operating expenses of $47.0 million produced a $5.1 million operating loss. Net loss improved to $4.3 million, or $0.10 per diluted share, while adjusted EBITDA was positive at $2.5 million. Revenue and gross profit grew faster than operating expenses, the leverage pattern needed for sustained profitability.

What does the latest cash position imply?

Cash and marketable securities were $144.7 million at March 31, 2026, against $35.6 million of debt. Quarterly operating cash use was $2.4 million, and capital expenditures were $1.1 million, largely for instrument trays. Liquidity supports launches, evidence generation, and expansion while reducing near-term financing pressure.

Which turning points shaped SI-BONE’s platform?

SI-BONE’s history is a sequence of category creation, platform expansion, and commercial scaling. Each milestone changed its addressable market or competitive position.

1. 2009
   Commercial launch of the original iFuse system established a minimally invasive SI joint fusion category and created the company’s core physician-training model.
2. 2017
   iFuse 3D introduced additive manufacturing, a fenestrated design, and a new generation of porous implant technology.
3. 2018
   The Nasdaq initial public offering increased financial resources and public-market accountability for commercial and clinical expansion.
4. 2021
   iFuse TORQ added a threaded porous implant architecture, broadening procedures and surgical approaches.
5. 2022
   iFuse Bedrock Granite extended the platform into spinopelvic fixation and gained FDA Breakthrough Device designation.
6. 2024
   iFuse INTRA and TORQ TNT widened access to interventional pathways and pelvic-trauma applications.
7. 2025
   European TORQ launch and additional reimbursement support strengthened the international and complex-procedure opportunity.

What changed strategically after the original iFuse?

The company evolved from a single-procedure franchise toward a broader platform for compromised sacropelvic bone. That can increase revenue per physician, diversify surgical approaches, and widen sites of care, but it also adds competitors, evidence requirements, reimbursement work, and training complexity.

What gives SI-BONE a competitive advantage?

SI-BONE’s moat combines anatomy-specific design, physician education, clinical publications, reimbursement experience, field support, intellectual property, and instrument access. Its clinical evidence overview shows how published outcomes support the iFuse platform.

These resources reinforce one another: evidence supports reimbursement and facility approval; training turns approval into physician use; field support helps repeat use; and broader products increase the value of each account. The weakness is scale. Diversified spine companies can spread sales, robotics, and contracting costs across much larger portfolios.

How durable is the intellectual-property position?

At December 31, 2025, SI-BONE owned 49 issued U.S. patents and had 24 pending U.S. applications. Original iFuse shape patents are expected to expire by August 2028, while iFuse 3D, Bedrock Granite, and TORQ have later-dated protection. The portfolio is layered, but patents can be challenged, designed around, or weakened by bundled hospital purchasing.

Why are training and clinical support part of the moat?

Adoption requires diagnosis, technical confidence, facility access, and reimbursement. Training and simulators reduce learning friction; clinical specialists support cases; published outcomes help physicians, payors, and hospital committees evaluate results. These assets create behavioral and institutional switching costs rather than contractual lock-in.

Who competes with SI-BONE, and where is it vulnerable?

SI-BONE competes with focused SI joint companies, spine-device manufacturers, trauma suppliers, and non-surgical alternatives. Its filings name Alphatec, Aurora Spine, Globus Medical, Medtronic, and Tenon Medical. Larger rivals can bundle implants with navigation, robotics, imaging, rods, screws, and hospital contracts, offsetting a specialist’s product differentiation.

What would weaken the moat?

The moat would weaken if outcomes lose differentiation, coverage deteriorates, patents expire without replacement innovation, or larger rivals restrict compatibility with navigation and robotic systems. Hospital bundling can also pressure price. SI-BONE must keep converting evidence and product innovation into physician productivity rather than relying on historical leadership.

How strong are SI-BONE’s margins, cash flow, and balance sheet?

FY2025 was an important scale milestone. Revenue reached $200.9 million, up 20.2%, and gross profit was $159.9 million at a 79.6% gross margin. Net loss narrowed to $18.9 million, while adjusted EBITDA turned positive at $8.9 million. The company also reported nearly cash-flow breakeven, with operating cash use of only $0.7 million for the year.

Why is gross margin central to the model?

Gross margin determines how quickly procedure growth absorbs sales, clinical-support, research, and public-company costs. Product mix, royalties, inventory reserves, supplier pricing, tariffs, and discounting can move the line. The challenge is to preserve margin while scaling newer products and international channels.

How much financial flexibility does SI-BONE have?

SI-BONE’s liquidity and improving cash conversion make it stronger than its accumulated deficit alone suggests. The next proof point is sustained positive operating cash flow after inventory, receivables, stock compensation, and instrument-tray investment.

Who owns SI-BONE stock, and how is the company governed?

SI-BONE has a single class of common stock with one-share-one-vote economics rather than founder-controlled dual-class shares. Ownership is institutionally concentrated, while insiders own a meaningful but non-controlling stake. The 2026 proxy statement reports beneficial ownership based on 44,201,473 shares outstanding at March 31, 2026.

What does the governance structure signal?

The board is majority independent, and chair and CEO roles are separated. SI-BONE nevertheless has a classified board, supermajority requirements for some amendments, limits on written consent, and other takeover defenses. These provisions support continuity but make rapid changes in control or board composition harder.

How are management incentives aligned?

Executive incentives combine revenue growth, adjusted EBITDA, operating goals, restricted stock, performance units, and relative shareholder return. The design encourages growth with improving profitability, although adjusted EBITDA should not be confused with GAAP earnings because excluded costs remain economically relevant.

Which opportunities and risks could change SI-BONE’s outlook?

SI-BONE’s opportunity set is attractive because several growth levers can work simultaneously: more trained physicians, higher procedure frequency, broader sites of care, new indications, international expansion, and portfolio adoption across multiple specialties. The company’s Bedrock Granite platform and TORQ TNT platform illustrate the move into complex spine and trauma workflows.

What are the most important growth drivers?

Which risks deserve the closest attention?

Which KPIs should students and investors monitor next?

The best KPI set links physician behavior to financial statements: physician activation, procedures, territory productivity, revenue, gross profit, operating leverage, and cash conversion. Revenue growth alone does not show whether adoption is durable or commercial costs are simply rising.

Researchers should compare each operating gain with the resources required to produce it. Improving utilization in an established territory is generally higher quality than equal revenue growth that depends on proportionate additions to sales coverage, inventory, or instrument trays.

How should the KPI chain be interpreted?

A high-quality quarter combines physician and utilization growth, stable pricing, gross margin near the established range, slower operating-expense growth, and positive cash conversion. Heavy hiring, rising inventory, slower collections, or discounting would weaken that signal. Working capital and instrument-tray capex are integral to SI-BONE’s economics.

Why does SI-BONE matter for valuation, and what is the key takeaway?

A SI-BONE discounted cash flow is most sensitive to revenue duration, mature operating margin, reinvestment, and sustained profitability. High gross margin creates leverage, but sales support, training, clinical research, development, and instrument trays require continuing investment. Gross margin is therefore not a proxy for mature profitability.

Which valuation assumptions matter most?

What is the analytical takeaway?

SI-BONE is evolving from a category-defining SI joint franchise into a broader sacropelvic platform. Its supports are clinical evidence, physician education, specialized execution, high gross margin, improving losses, and liquidity. Constraints include U.S. concentration, reimbursement, bundled-system competitors, supplier and regulatory execution, and proving that new products can scale without rebuilding costs for each adjacency.